The Regulatory Challenges of Placing Dietary Ingredients on the European and US Market.

IF 1.9 Q3 NUTRITION & DIETETICS Journal of Dietary Supplements Pub Date : 2024-01-25 DOI:10.1080/19390211.2024.2308261
M J Tallon, D S Kalman
{"title":"The Regulatory Challenges of Placing Dietary Ingredients on the European and US Market.","authors":"M J Tallon, D S Kalman","doi":"10.1080/19390211.2024.2308261","DOIUrl":null,"url":null,"abstract":"<p><p>The DSHEA is 30 years old and its place in providing legitimate protections for public health through relevant agency oversight has created a patchwork of legal and scientific requirements. In contrast, the European Union has rules on supplements and permitted ingredients. Given the context of a global supply chain for food ingredients any conflict between the legality of ingredients between the U.S/EU can inhibit the economic viability of international trade. The purpose of this review is to contrast these different systems of legislative oversight. The analysis of both markets demonstrates a fragmentation in what are considered legal food ingredients between country wide harmonization and state rules and related interpretation. There are many commonalities in this regard between the U.S/EU, from borderline medicinal classifications to their resultant preclusion from food use. However, the codified legal system existing within the EU and excessive guidance can be viewed as time consuming and inflexible, especially for placing new ingredients on the market. The US in contrast is in a holding pattern for legislative interpretation regarding NDIs, GRAS and possible drug preclusion laws. As we hit the anniversary of the DSHEA recent commentary from U.S./EU central authorities point to increased international co-operation in ingredient safety assessments but whether this results in friction-free access between markets is to be determined.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dietary Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/19390211.2024.2308261","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

The DSHEA is 30 years old and its place in providing legitimate protections for public health through relevant agency oversight has created a patchwork of legal and scientific requirements. In contrast, the European Union has rules on supplements and permitted ingredients. Given the context of a global supply chain for food ingredients any conflict between the legality of ingredients between the U.S/EU can inhibit the economic viability of international trade. The purpose of this review is to contrast these different systems of legislative oversight. The analysis of both markets demonstrates a fragmentation in what are considered legal food ingredients between country wide harmonization and state rules and related interpretation. There are many commonalities in this regard between the U.S/EU, from borderline medicinal classifications to their resultant preclusion from food use. However, the codified legal system existing within the EU and excessive guidance can be viewed as time consuming and inflexible, especially for placing new ingredients on the market. The US in contrast is in a holding pattern for legislative interpretation regarding NDIs, GRAS and possible drug preclusion laws. As we hit the anniversary of the DSHEA recent commentary from U.S./EU central authorities point to increased international co-operation in ingredient safety assessments but whether this results in friction-free access between markets is to be determined.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
将膳食添加剂投放到欧洲和美国市场所面临的监管挑战。
DSHEA 已有 30 年的历史,它通过相关机构的监督为公众健康提供合法的保护,这就造成了法律和科学要求的错综复杂。相比之下,欧盟则有关于补充剂和允许成分的规定。鉴于食品配料的全球供应链背景,美国和欧盟之间配料合法性的任何冲突都会抑制国际贸易的经济可行性。本综述旨在对比这两种不同的立法监督体系。对这两个市场的分析表明,在国家范围内的协调和各州的规则及相关解释之间,被视为合法的食品配料是分散的。在这方面,美国和欧盟有许多共同点,从边缘药用分类到因此被排除在食品用途之外。然而,欧盟现有的成文法律体系和过多的指导意见可能会被视为费时费力且缺乏灵活性,尤其是在将新成分投放市场时。与此相反,美国在有关非食用物质(NDI)、GRAS 和可能的药物禁用法的立法解释方面则处于停滞状态。在《药品安全和健康管理法》(DSHEA)颁布一周年之际,美国/欧盟中央主管机构最近发表的评论指出,在成分安全评估方面的国际合作将得到加强,但这是否会导致市场间的无摩擦准入还有待确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Dietary Supplements
Journal of Dietary Supplements Agricultural and Biological Sciences-Food Science
CiteScore
6.10
自引率
0.00%
发文量
34
期刊介绍: The Journal of Dietary Supplements (formerly the Journal of Nutraceuticals, Functional & Medical Foods) has been retitled to reflect the bold departure from a traditional scientific journal presentation to a leading voice for anyone with a stake in dietary supplements. The journal addresses important issues that meet the broad range of interests from researchers, regulators, marketers, educators, and health professionals from academic, governmental, industry, healthcare, public health, and consumer education sectors. This vital tool not only presents scientific information but interprets it - helping you more readily pass it on to your students, patients, clients, or company.
期刊最新文献
Caffeic Acid: Numerous Chemoprotective Effects are Mediated via Hormesis. Biochemical and Histopathological Evidence on Beneficial Effects of Standardized Extract from Tragopogon graminifolius as a Dietary Supplement in Fatty Liver: Role of Oxidative Stress. Efficacy of Dichrostachys Glomerata Supplementation on Overweight and Mildly Obese Adult's Weight, Mood, and Health-Related Quality of Life: A Randomized Double-Blind Placebo-Controlled Trial. Effects of an Isotonic Beetroot Drink on Power Output During Sprint Exercise and Jump Performance in Physically Active Individuals: A Randomized Crossover Trial. Dietary Collagen Peptides Ameliorate the Mood Status of Fatigue and Vigor: A Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Comparative Trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1